2018 IMPAACT Annual Meeting Treatment Scientific Committee Presentations

Welcome and Overview of Treatment Scientific Agenda

Overview of Recent Findings on Dolutegravir

Implications of Recent DTG Findings for IMPAACT 2010/VESTED

Panel Discussion: Clinical Implications and Community Perspectives

Moderator: Elaine Abrams

P1026s, Focus on TAF: Pharmacokinetic Properties of Antiretrovirals Therapy During Pregnancy

P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

Ted Ruel

P1101: Phase I/II Dose-Finding, Safety, Tolerance, & PK Study of Raltegravir-Containing ART Regimen in HIV-Infected & TB Co-Infected Children

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

P1110: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-Exposed Infants at High Risk

Updates on Treatment Studies Enrolling, Pending and In-development

Elaine Abrams and
Ted Ruel